Amgen's Early Melanoma Data: Analysts 'Overall' in Wait Mode

By Randy OsborneStaff Writer

Wednesday, March 20, 2013

Amgen Inc.'s $1 billion buyout in 2011 of BioVex Group Inc., which brought aboard the melanoma therapy then known as OncoVex, may be paying off, but analysts are waiting for overall survival (OS) Phase III data before they start jumping up and down about the compound, now called talimogene laherparepvec, or T-VEC.